肿瘤细胞治疗研究
ALL SOURCES
Bicistronic CD19/CD22 CAR T-Cell Therapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: A Nonrandomized Clinical Trial.
在这项非随机临床试验中，双顺反子 CD19/CD22 CAR-T 细胞疗法在儿童 B-ALL 中诱导了高比例的微小残留病阴性缓解，并具有持久的 EFS。这些发现支持在前瞻性试验中进一步评估。
Hattrick against Lymphoma with Trispecific CAR T Cells.
Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22.
In vivo engineering of T cells with a synthetic cytokine receptor enables selective enrichment and expansion of anti-CD22 CAR T cells.
Adult acute lymphoblastic leukemia: incorporation of recent advances into current treatment strategies.
Differential cytokine architecture in patients treated with CART19 versus CART22.
这些发现揭示了 IL-10 是一种强效的 CRS 缓解因子，并支持通过增强 IL-10 策略来提高 CAR-T 的安全性。
CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial results.
CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute
这是一项 II 期注册临床试验，评估 CD22T 细胞治疗急性淋巴细胞白血病的疗效与安全性。当前状态：招募中。计划入组 20 例。试验地点：美国 · 贝塞斯达（共 1 个中心）。登记号：NCT07328503。
Preinfusion risk factors for the development of severe neurotoxicity following CART therapy in pediatric patients.
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
这是一项 I/II 期注册临床试验，评估 CD19T 细胞治疗非霍奇金淋巴瘤、白血病、急性淋巴细胞白血病的安全性、可行性及初步疗效。当前状态：招募中。计划入组 130 例。试验地点：美国 · 贝塞斯达（共 1 个中心）。登记号：NCT05442515。
MEMBER ACCOUNT
登录成功会直接打开下一页。
